Search Result

Results for "

structural analogue

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (1) Apoptosis (1) Bacterial (4) Biochemical Assay Reagents (1) Cannabinoid Receptor (1) CETP (1) CMV (1) Drug Derivative (4) Drug Intermediate (1) Drug Isomer (1) Drug Metabolite (1) Endogenous Metabolite (6) Epigenetic Reader Domain (1) Flavivirus (1) Fluorescent Dye (1) Fungal (3) GABA Receptor (1) GLUT (1) GPR55 (1) GPR68 (1) HIV (2) HSV (1) Molecular Glues (2) Oxytocin Receptor (1) Parasite (3) Potassium Channel (3) Prostaglandin Receptor (1) Ras (1) Reference Standards (2) TNF Receptor (3) Topoisomerase (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (3) Endocrinology (2) Infection (10) Metabolic Disease (3) Neurological Disease (13)

By Targets:

Akt (2)

Anaplastic lymphoma kinase (ALK) (1)

Androgen Receptor (1)

Apoptosis (1)

Bacterial (4)

Biochemical Assay Reagents (1)

Cannabinoid Receptor (1)

CETP (1)

CMV (1)

Drug Derivative (4)

Drug Intermediate (1)

Drug Isomer (1)

Drug Metabolite (1)

Endogenous Metabolite (6)

Epigenetic Reader Domain (1)

Flavivirus (1)

Fluorescent Dye (1)

Fungal (3)

GABA Receptor (1)

GLUT (1)

GPR55 (1)

GPR68 (1)

HIV (2)

HSV (1)

Molecular Glues (2)

Oxytocin Receptor (1)

Parasite (3)

Potassium Channel (3)

Prostaglandin Receptor (1)

Ras (1)

Reference Standards (2)

TNF Receptor (3)

Topoisomerase (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (13)

Cardiovascular Disease (3)

Endocrinology (2)

Infection (10)

Metabolic Disease (3)

Neurological Disease (13)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117109

Amino Tadalafil	Drug Derivative	Others
Amino Tadalafil is a structural analogue of Tadalafil (HY-90009A). Tadalafil is a potent inhibitor of PDE5 with applications in several conditions, including erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract dysfunction .

HY-50848

BW A868C	Prostaglandin Receptor	Cardiovascular Disease
BW A868C, a hydantoin compound, is a BW245C structural analogue. BW A868C is a selective and potent competitive prostaglandin D2 (PGD2) antagonist. BW A868C has no effect on other prostaglandin receptors (IP, EP1, EP2, TP and FP) .

HY-150102

EPI-7170	Androgen Receptor	Cancer
EPI-7170, a ralaniten analogue, is a potent *androgen receptor N-terminal structural* domain** antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC) .

HY-15966A

GSK2110183 analog 1 hydrochloride	Akt	Cancer
GSK2110183 analog 1 hydrochloride is the structural analogue of GSK2110183.

HY-15966

GSK2110183 analog 1	Akt	Cancer
GSK2110183 analog 1 is the structural analogue of GSK2110183.

HY-106848

Arteflene Ro 42-1611	Parasite	Infection
Arteflene is a synthetic structural analogue of artemisinin. Arteflene has antimalarial activity .

HY-169704

Ogerin analogue 1	GPR68	Neurological Disease
Ogerin analogue 1 (compound 20) is a structural analog of Ogerin (HY-110279). Ogerin analogue 1 is generally used as a negative control .

HY-N12519

1,2-Didehydrocryptotanshinone	Others	Others
1,2-Didehydrocryptotanshinone is a structural analogue of cryptotanshinone (CT) (HY-N0174) .

HY-103503

CGP13501	GABA Receptor	Neurological Disease
CGP13501 is a positive allosteric modulator of GABAB receptor. CGP13501 is a structural analogue of propofol .

HY-P0258

Mas7 Mastoparan 7	Apoptosis	Cardiovascular Disease Neurological Disease
Mas7 (Mastoparan 7), a structural analogue of mastoparan, is an activator of heterotrimeric Gi proteins and its downstream effectors.

HY-Y1373S1

Cyclohexanecarboxylic acid-d11	Endogenous Metabolite	Neurological Disease
Cyclohexanecarboxylic acid-d₁₁ is the deuterium labeled Cyclohexanecarboxylic acid . Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .

HY-Y1373S

Cyclohexanecarboxylic acid-d1	Endogenous Metabolite	Neurological Disease
Cyclohexanecarboxylic acid-d₁ is the deuterium labeled Cyclohexanecarboxylic acid . Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .

HY-128977

CD235	Epigenetic Reader Domain	Cancer
CD235 is a structurally similar analogue of CD161. CD161 is a potent and orally bioavailable BET bromodomain inhibitor .

HY-125062

Steviolmonoside Glucosilsteviol	GLUT	Metabolic Disease
Steviolmonoside (Glucosilsteviol) is a structural analogue of steviol. Steviolmonoside decreases glucose production and inhibits oxygen uptake in rat renal cortical tubules .

HY-131583

MP265 4-Chlorobenzyl carbamimidothioate hydrochloride	Bacterial	Infection
MP265 (4-Chlorobenzyl carbamimidothioate hydrochloride) is a structural analogue of A22 but is less toxic. MP265 is a MreB inhibitor .

HY-P3221

[Leu3]-Oxytocin	Oxytocin Receptor	Endocrinology
[Leu3]-Oxytocin, an oxytocin analogue, is derived by structural variation in sequence position 3 replaced by leucine (Leu) .

HY-Y1373R

Cyclohexanecarboxylic acid (Standard) Hexahydrobenzoic acid (Standard)	Reference Standards Endogenous Metabolite	Neurological Disease
Cyclohexanecarboxylic acid (Standard) is the analytical standard of Cyclohexanecarboxylic acid. This product is intended for research and analytical applications. Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .

HY-Y1373

Cyclohexanecarboxylic acid Hexahydrobenzoic acid	Endogenous Metabolite Drug Intermediate	Neurological Disease
Cyclohexanecarboxylic acid is a Valproate structural analogue. Cyclohexanecarboxylic acid is an essential intermediate for the aromatization of Shikimic acid (HY-N0130) by mammals. Cyclohexanecarboxylic acid has anticonvulsant action .

HY-137593A

N6-Etheno-nicotinamide dinucleotide phosphate trisodium ε-NADP+ trisodium	Drug Derivative	Metabolic Disease
N6-Etheno-nicotinamide dinucleotide phosphate (ε-NADP+) trisodium, a structural analogue of the NADP(+), is a maize malic enzyme inhibitor with a K_i of 1.01 μM .

HY-106662

Chloroquinoxaline sulfonamide Chloroquinoxaline; NSC-339004	Molecular Glues Topoisomerase Parasite	Infection Cancer
Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle . Antitumor activity .

HY-123239

KLS-13019	GPR55	Neurological Disease
KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats .

HY-123039

CP-532623	CETP	Metabolic Disease
CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties .

HY-124013

NBDA 4-(α-N-L-alanine)-NBD	Fluorescent Dye	Others
NBDA (4-(α-N-L-alanine)-NBD) is a structural and functional analogue of the 2,4-dinitrophenyl group (DNP). NBDA can be used to detect and characterize antinitroaromatic antibodies, even in crude preparations, and possibly on cell surfaces .

HY-W002039

3-Amino-3-phenylpropionic acid DL-β-Phenylalanine	Biochemical Assay Reagents	Endocrinology
3-Amino-3-phenylpropionic acid (DL-β-Phenylalanine) is a structural GABA analogue. 3-Amino-3-phenylpropionic acid inhibits baclofen (HY-B0007) induced gastric acid secretion .

HY-112140

JH-VIII-157-02	Anaplastic lymphoma kinase (ALK)	Cancer
JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC₅₀ of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells.

HY-153723

BI-2493	Ras	Cancer
BI-2493 is a structural analogue of BI-2865 and a highly selective and orally active pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research .

HY-W031471A

Pyrazine-2-amidoxime	Bacterial Fungal	Infection
Pyrazine-2-amidoxime is a structural analogue of pyrazine-2-carboxamide with antimicrobial activity. Pyrazine-2-amidoxime shows killing and inhibiting properties against Candida albicans, fungal pathogen and Gram-positive bacteria .

HY-101445B

(S)-Trolox	Drug Isomer	Neurological Disease
(S)-Trolox is an analogue of vitamin E, in which the phytyl chain is replaced with a carboxyl group. (S)-Trolox is frequently used as a model compound for studies of structural features, as well as a standard for evaluation of antioxidant activity. (S)-Trolox has potent and specific neuroprotective and antioxidant effects .

HY-120954

14,15-EE-5(Z)-E	Endogenous Metabolite	Cardiovascular Disease
14,15-EE-5(Z)-E is a structural analogue of 14, 15-epoxide dicartrienoic acid (14,15-EET). 14,15-EE-5(Z)-E antagonizes the relaxation of vascular smooth muscle induced by EET .

HY-106662R

Chloroquinoxaline sulfonamide (Standard)	Molecular Glues Topoisomerase Parasite	Infection Cancer
Chloroquinoxaline sulfonamide (Standard) is the analytical standard of Chloroquinoxaline sulfonamide. This product is intended for research and analytical applications. Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle . Antitumor activity .

HY-131606B

Cidofovir diphosphate tri(triethylamine)	Drug Metabolite	Infection
Cidofovir diphosphate tri triethylamine is an active intracellular metabolite of Cidofovir. Cidofovir diphosphate tri triethylamine is a selective inhibitor of viral DNA polymerases with K_i values of 6.6, 0.86 and 1.4 μM for HCMV, HSV-1 and HSV-2 DNA polymerase, respectively .

HY-131606

Cidofovir diphosphate	HSV CMV	Infection
Cidofovir diphosphate is an active intracellular metabolite of Cidofovir. Cidofovir diphosphate is a selective inhibitor of viral DNA polymerases with K_i values of 6.6, 0.86 and 1.4 μM for HCMV, HSV-1 and HSV-2 DNA polymerase, respectively .

HY-117109R

Amino Tadalafil (Standard)	Reference Standards Drug Derivative	Others
Amino Tadalafil (Standard) is the analytical standard of Amino Tadalafil. This product is intended for research and analytical applications. Amino Tadalafil is a structural analogue of Tadalafil (HY-90009A). Tadalafil is a potent inhibitor of PDE5 with applications in several conditions, including erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract dysfunction .

HY-100197

Synaptamide 1 Publications Verification N-Docosahexaenoyl ethanolamine (DHEA); Docosahexaenoyl ethanolamide	Cannabinoid Receptor	Neurological Disease
Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .

HY-15643A

LY 303511 hydrochloride 3 Publications Verification	TNF Receptor Potassium Channel	Cancer
LY 303511 hydrochloride is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K ⁺ currents (IC₅₀=64.6±9.1 μM) in MIN6 insulinoma cells.

HY-15643

LY 303511	TNF Receptor Potassium Channel	Cancer
LY303511 is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K ⁺ currents (IC₅₀=64.6±9.1 μM) in MIN6 insulinoma cells.

HY-15643B

LY 303511 dihydrochloride	TNF Receptor Potassium Channel	Cancer
LY 303511 dihydrochloride is a structural analogue of LY294002. LY 303511 dihydrochloride does not inhibit PI3K. LY 303511 dihydrochloride enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY 303511 dihydrochloride reversibly blocks K ⁺ currents (IC₅₀=64.6±9.1 μM) in MIN6 insulinoma cells.

HY-134635

Dehydrozingerone	Bacterial Fungal HIV	Infection Neurological Disease Cancer
Dehydrozingerone (Compound 10), a structural half analogue of Curcumin (HY-N0005), is a phenolic compound with antibacterial, anticancer, antioxidant, anti-Alzheimer’s and antifungal activity, which is isolated from ginger (Zingiber officinale) rhizomes. Dehydrozingerone shows moderate inhibitory activities on the secretion of HBsAg in HepG 2 cells with an IC₅₀ value of 0.50 mM .

HY-168364

1(R),2(S)-epoxy Cannabidiol	Wnt β-catenin Drug Derivative	Neurological Disease
1(R),2(S)-epoxy Cannabidiol (Compound 2a) is a structural analogue of phytocannabinoidsphytocannabinoids. 1(R),2(S)-epoxy Cannabidiol exhibits potent inhibitory activity against Wnt/β-catenin pathway. 1(R),2(S)-epoxy Cannabidiol is promising for research of neuroprotective agents .

HY-W015764

T-1105 1 Publications Verification	Flavivirus	Infection
T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase .

HY-W007656

Cyclen	Others	Others
Cyclen is a macrocyclic tetraamine. Cyclen is the aza analogue of crown ether, used as a precursor for MRI contrast agents, and is an intermediate for the preparation of effective macrocyclic chelates. Cyclen is employed as a structural regulator through interfacial polymerization of polyethleneimine (PEI) and trimesoyl chloride (TMC) to develop polyamide NF membrane with efficient Li ⁺/Mg ²⁺ separation performance. Cyclen has specific cavity structure and exhibits selective coordination properties for Li ⁺ ions .

HY-134635R

Dehydrozingerone (Standard)	Bacterial Fungal HIV	Infection Neurological Disease Cancer
Dehydrozingerone (Standard) is the analytical standard of Dehydrozingerone. This product is intended for research and analytical applications. Dehydrozingerone (Compound 10), a structural half analogue of Curcumin (HY-N0005), is a phenolic compound with antibacterial, anticancer, antioxidant, anti-Alzheimer’s and antifungal activity, which is isolated from ginger (Zingiber officinale) rhizomes. Dehydrozingerone shows moderate inhibitory activities on the secretion of HBsAg in HepG 2 cells with an IC50 value of 0.50 mM .

HY-128131

UCCF-029 free base	Endogenous Metabolite	Others
UCCF-029 Free base is a potent activator of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. UCCF-029 Free base exhibits enhanced activity through benzannulation of the flavone A-ring at the 7,8-position. UCCF-029 Free base serves as a structural guide for the development of more effective flavonoid analogues. UCCF-029 Free base demonstrates improved potency compared to apigenin in activating wild-type CFTR. UCCF-029 Free base also exhibits potential for activating the mutant CFTR (G551D-CFTR) though not as robustly as apigenin.

Cat. No.	Product Name

HY-L044

Nucleotide Compound Library	562 compounds
Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications. MCE offers a unique collection of 562 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).

Nucleotide Compound Library

562 compounds

Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications.

MCE offers a unique collection of 562 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).

HY-L043

Lipid Compound Library	1,525 compounds
Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies. MCE supplies a unique collection of 1,525 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

Lipid Compound Library

1,525 compounds

Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies.

MCE supplies a unique collection of 1,525 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

HY-L0120V

Asinex BioDesign Library

170,269 compounds

“BioDesign” approach incorporates key structural features of known pharmacologically relevant natural products (e.g. alkaloids and other secondary metabolites) into synthetically feasible medicinal chemistry scaffolds. In order to identify the privileged pharmacophores, ring systems and linkers, we have carried out statistical analysis of structural features of natural products, marketed drugs, and drug candidates.

Saturated, fused ring, spiro, and bridged systems with a tendency towards multiple chiral centers are highly privileged among natural products and marketed drugs yet these structures are very poorly represented in commercial libraries. This library addressed this market need by incorporating these privileged elements into the design of novel synthetic molecules with high molecular framework diversity, multiple stereogenic centers (≥2), and degree of saturation (Fsp3 > 0.5).

Cat. No.	Product Name	Type